Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

This study has been terminated.
(Lack of efficacy)
Sponsor:
Information provided by (Responsible Party):
Anthera Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01130246
First received: April 19, 2010
Last updated: October 30, 2012
Last verified: October 2012
  Purpose

The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).


Condition Intervention Phase
Acute Coronary Syndrome
Drug: A-002, varespladib methyl
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes

Further study details as provided by Anthera Pharmaceuticals:

Primary Outcome Measures:
  • Primary Objective of the Study [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    To determine whether 16 weeks of treatment with A-002 plus atorvastatin and standard of care is superior to placebo plus atorvastatin and standard of care for reducing the hazard of the first occurrence of the combined endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or documented unstable angina with objective evidence of ischemia requiring hospitalization.


Secondary Outcome Measures:
  • Secondary Objective of the Study [ Time Frame: 2, 4, 8, 16 weeks and 6 months ] [ Designated as safety issue: No ]
    To determine whether A-002 plus atorvastatin and standard of care is superior to placebo plus atorvastatin and standard of care for reducing the occurrence of the hazard of the combined endpoint of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke or documented unstable angina with objective evidence of ischemia requiring hospitalization or multiple occurrences of the non-fatal components of the composite primary endpoint.


Enrollment: 5189
Study Start Date: May 2010
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A-002 500 mg
Once daily oral administration
Drug: A-002, varespladib methyl
A-002 administered once daily in addition to atorvastatin and standard of care
Placebo Comparator: Matched Placebo
Once daily oral administration
Drug: Placebo
Placebo administered once daily in addition to atorvastatin and standard of care

Detailed Description:

A double-blind randomized parallel group placebo controlled study in subjects presenting with an ACS. Up to 6500 subjects will be randomized to receive either A-002 500 mg once daily (QD) or placebo tablets in addition to atorvastatin QD and standard of care. Treatment will be 16 weeks in duration. The dose of atorvastatin shall be adjusted after 8 weeks if subject's LDL-C is ≥100 mg/dL, but otherwise must remain stable throughout the16-week duration of study. The survival status for all enrolled subjects will be ascertained 6 months after they complete the study.

Randomization must occur within ≤96 hours of hospitalization for the index ACS event, or if already hospitalized, within ≤96 hours of index event diagnosis. Follow-up visits will occur on Weeks 1, 2, 4, 8, and 16. A 6 month follow-up visit will also occur.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women ≥40 years of age
  2. Written informed consent from the subject
  3. A diagnosis of unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment elevation myocardial infarction (STEMI)

    Unstable angina is defined as:

    • Chest pain symptomatic of ischemia or angina occurring at rest or on minimal exertion with a pattern of increasing frequency or severity, lasting >10 minutes and consistent with myocardial ischemia within 24 hours prior to hospitalization and
    • New or dynamic ST-segment depression or prominent T-wave inversion changes in at least 2 contiguous leads and
    • In addition subjects meeting the above criteria for unstable angina must also have either troponin I, troponin T or CKMB above the LLD but below the 99th percentile of the upper reference limit (URL) and not due to cardioversion or underlying cardiovascular (CHF, cardiomyopathy) or renal disease

    NSTEMI is defined as:

    • Chest pain symptomatic of ischemia
    • No electrocardiogram (ECG) changes, or ST-depression, or T wave changes(i.e., no new Q waves on serial ECGs)and
    • Increase in cardiac troponin > local limit for the definition of myocardial infarction or increase in CK-MB isoenzyme > URL

    STEMI is defined as:

    • Chest pain symptomatic of ischemia
    • ST segment elevation and associated T wave changes or ST-segment elevation of at least 2 mm in 2 contiguous leads, either of which persisting for longer than 15 minutes and
    • Increase in cardiac troponin > local limit for the definition of myocardial infarction or increase in CK-MB >URL
  4. All subjects must have the presence of at least one of the following risk factors:

    • Diabetes Mellitus or
    • Presence of any 3 of the following characteristics of metabolic syndrome

      • Waist circumference >102 cm in males, >88 cm in females
      • Serum triglycerides ≥150 mg/dL (≥1.7 mmol/L)
      • HDL-C <40 mg/dL (<1 mmol/L) in males, <50 mg/dL (<1.3 mmol/L) in females
      • Blood pressure ≥130/85 mmHg
      • Plasma glucose ≥110 mg/dL (≥6.1 mmol/L) or
    • history of cerebrovascular disease (stroke or TIA) or
    • history of peripheral vascular disease or
    • previous CABG or
    • previous documented myocardial infarction or
    • previous coronary revascularization
  5. Subjects must be randomized within ≤96 hours of hospital admission for the index event, or if already hospitalized, within ≤96 hours of index event diagnosis
  6. Revascularization, if required or planned, must occur prior to randomization

Exclusion Criteria:

  1. Subjects enrolled in another experimental (interventional)protocol within the past 30 days prior to Screening.
  2. Subjects treated for cancer within the previous 5 years except for skin basal cell carcinoma or carcinoma in situ of the cervix, with measures other than a minor, complete surgical excision or radiation therapy (e.g. chemotherapy)
  3. The presence of any severe liver disease with cirrhosis, active hepatitis, active chronic hepatitis, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 x ULN, biliary obstruction with hyperbilirubinemia (total bilirubin >2 x ULN)
  4. Active cholecystitis, gall bladder symptoms, or any hepatobiliary abnormalities
  5. The presence of severe renal impairment (creatinine clearance [CrCl] <30 mL/min or creatinine >3 x ULN),nephrotic syndrome, or subjects undergoing dialysis
  6. Uncontrolled diabetes mellitus (known hemoglobin A1c [HbA1c] >11% within the last 1 month prior to Screening)
  7. Females who are nursing, pregnant, or intend to become pregnant during the time of the study, or females of childbearing potential who have a positive pregnancy test during screening evaluation. Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy. A reliable method for this study is defined as one of the following: oral or injectable contraceptives, intrauterine device (IUD), contraceptive implants, tubal ligation, hysterectomy, a double barrier method (diaphragm with spermicidal foam or jelly, or a condom).
  8. Subjects who have a history of alcohol or drug abuse within 1 year of study entry
  9. Subjects living too far from participating center or unable to return for follow-up visits
  10. Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk for therapy with an investigational drug, are unreliable, or have an incomplete understanding of the study which may affect their ability to take drugs as prescribed or comply with instructions
  11. Known human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), or tuberculosis infection
  12. Acute bacterial, fungal or viral infection
  13. Subjects currently taking drugs that are potent inhibitors of cytochrome P450 unless they can be withdrawn
  14. Subjects with New York Heart Association (NYHA) Class III or IV heart failure, or if known, left ventricular ejection fraction (LVEF) <30
  15. Subjects with moderate or severe aortic stenosis, aortic regurgitation, mitral stenosis or mitral regurgitation
  16. Ventricular arrhythmias requiring chronic drug treatment or implantable cardioverter-defibrillator (ICD)
  17. Subjects with no stenosis or stenosis <50% on angiography, if known
  18. Subjects with a pacemaker or persistent left bundle branch block (LBBB)
  19. Fasting triglyceride levels of ≥400 mg/dL (4.5 mmol/L)
  20. Subjects who have a history of statin intolerance or a significant myopathy or rhabdomyolysis with any lipid altering drugs
  21. Subjects currently treated with the maximum labeled dose of a statin and not at LDL-C target for their level of risk as defined by NCEP ATP III
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01130246

  Show 362 Study Locations
Sponsors and Collaborators
Anthera Pharmaceuticals
  More Information

No publications provided by Anthera Pharmaceuticals

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Anthera Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01130246     History of Changes
Other Study ID Numbers: AN-CVD2233
Study First Received: April 19, 2010
Last Updated: October 30, 2012
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Germany: Federal Institute for Drugs and Medical Devices
Italy: Ministry of Health
Netherlands: Medicines Evaluation Board (MEB)
Poland: Ministry of Health
Georgia: Ministry of Health
Russia: Pharmacological Committee, Ministry of Health
Spain: Spanish Agency of Medicines
Ukraine: Ministry of Health
Australia: Department of Health and Ageing Therapeutic Goods Administration
India: Drugs Controller General of India
Czech Republic: Ethics Committee
Hungary: Research Ethics Medical Committee

Additional relevant MeSH terms:
Acute Coronary Syndrome
Syndrome
Angina Pectoris
Cardiovascular Diseases
Chest Pain
Disease
Heart Diseases
Myocardial Ischemia
Pain
Pathologic Processes
Signs and Symptoms
Vascular Diseases
Varespladib methyl
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phospholipase A2 Inhibitors

ClinicalTrials.gov processed this record on November 19, 2014